Search - tctmd.com

Displaying 1 - 20 of 198

Sort: Relevancy | Date

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

L.A. McKeown

August 12, 2025

News Industry News

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

June 12, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

L.A. McKeown

March 10, 2025

News Daily News

Philips Recalls Tack Endovascular Systems and Stops Distribution

L.A. McKeown

March 03, 2025

News Industry News

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

January 21, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Industry News

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

June 18, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Daily News

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

Todd Neale

May 03, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

L.A. McKeown

March 09, 2024

News Daily News

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

L.A. McKeown

March 01, 2024

Advertisement

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

What’s Going to Be Hot at TCT 2025

Coronary DCB Works Well in Multilayer In-Stent Restenosis: AGENT IDE Subanalysis

Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

Philips Recalls Tack Endovascular Systems and Stops Distribution

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

Top Endovascular News of 2024

Top Coronary Artery Disease News in 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Cordis Announces Positive 24-Month Results from Superficial Femoral Artery Study, Confirming Sustained Benefits of SELUTION SLR™ (sustained limus release) Drug-Eluting Balloon in Complex Patients

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

As US Rollout Begins for Coronary DCBs, Interventionalists Mull Practice Changes

FDA Approves Bioresorbable Scaffold for BTK Lesions

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

Agent Coronary DCB Gets FDA Approval for In-Stent Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content